List of works - Roberta Zappasodi

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab

scientific article published on 27 August 2014

Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations

scientific article published on 27 August 2015

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

scientific article published on 11 August 2020

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

scientific article published on 17 February 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

scientific article (publication date: 3 April 2015)

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

scientific article published on 26 February 2014

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

scientific article published on 04 July 2019

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

scientific article

Immunotherapy advances in uro-genital malignancies

scientific article

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

scientific article published on 30 September 2010

Lymphoma Immunotherapy: Current Status

scientific article

MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT

scientific article published in 2022

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

scientific article published on 21 July 2017

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

scientific article published on 26 March 2014

Rational design of anti-GITR-based combination immunotherapy

scientific article published on 29 April 2019

Sialidase NEU4 is involved in glioblastoma stem cell survival.

scientific article published on 21 August 2014

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

scientific article published on 09 June 2015

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells

scientific article published on 25 August 2008

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

scientific article published on 22 May 2019

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

scientific article published on 21 September 2010

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

scientific article published on 22 September 2008

List of works by Roberta Zappasodi

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab

Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

Immunotherapy advances in uro-genital malignancies

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

Lymphoma Immunotherapy: Current Status

MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.

Rational design of anti-GITR-based combination immunotherapy

Sialidase NEU4 is involved in glioblastoma stem cell survival.

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.